Sage Journals: Discover world-class research

Open access

Research article

First published 2017

Anti-CD20 Cell Therapies in Multiple Sclerosis—A Fixed Dosing Schedule for Ocrelizumab is Overkill

Jagannadha Avasarala

Drug Target Insights

Open access

Research article

First published 2022-1

Tolerability and Safety of Switching from Rituximab to Ocrelizumab: Evaluating Factors Associated with Infusion Related Reactions

Enrique Alvarez, Kavita V. Nair, Stefan Sillau [...]

Multiple Sclerosis Journal – Experimental,Translational and Clinical

Open access

Research article

First published 2025-10

Transition from anti-CD20 therapies to fumarates as a treatment strategy: A multicenter,retrospective observational experience

Brandi L Vollmer, Tammy Hoyt, Timothy W West [...]

Multiple Sclerosis Journal – Experimental,Translational and Clinical

Retricted access

Research article

First published 2024-2

Extended interval dosing of ocrelizumab in patients with multiple sclerosis is not associated with meaningful differences in disease activity

Nicole Bou Rjeily, Kathryn C Fitzgerald, Ellen M Mowry

Multiple Sclerosis Journal

Open access

Research article

First published 2024-04

Different lymphocyte counts of multiple sclerosis patients treated with ofatumumab and ocrelizumab: A retrospective observational study

Christoph Friedli, Nik Krajnc, Helly N. Hammer [...]

Journal of Central Nervous System Disease

Open access

Research article

First published 2019-1

Specific aspects of immunotherapy for multiple sclerosis in Switzerland: A structured commentary

L Achtnichts, A Chan, A Czaplinski [...]

Clinical and Translational Neuroscience

Open access

Review article

First published 2018

Ocrelizumab: a new milestone in multiple sclerosis therapy

Patricia Mulero, Luciana Midaglia, Xavier Montalban

Therapeutic Advances in Neurological Disorders

Search results

Anti-CD20 Cell Therapies in Multiple Sclerosis—A Fixed Dosing Schedule for Ocrelizumab is Overkill

Tolerability and Safety of Switching from Rituximab to Ocrelizumab: Evaluating Factors Associated with Infusion Related Reactions

Transition from anti-CD20 therapies to fumarates as a treatment strategy: A multicenter,retrospective observational experience

Extended interval dosing of ocrelizumab in patients with multiple sclerosis is not associated with meaningful differences in disease activity

Different lymphocyte counts of multiple sclerosis patients treated with ofatumumab and ocrelizumab: A retrospective observational study

Specific aspects of immunotherapy for multiple sclerosis in Switzerland: A structured commentary

Ocrelizumab: a new milestone in multiple sclerosis therapy